GUMDROP : A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects with Metastatic Castration-resistant Prostate Cancer (mCRPC)

Created by Nancy Dawson, last modified on Apr 28, 2013
Description:PSMA ADC 2301 is a Phase 2, open-label, study to assess the anti-tumor activity and tolerability of PSMA ADC in subjects with metastatic castration-resistant prostate cancer (mCRPC). Subjects must have received at least one taxane-containing chemotherapy regimen (e.g. docetaxel, cabazitaxel).
Link:http://clinicaltrials.gov/ct2/show/NCT01695044
Site:Johns Hopkins University
Principal Investigator:Contact: Michele Besche     410-328-8610